読み込み中
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
前日終値
$6.39
+$0.21 · +3.40%
日中の時刻はETです。市場データは遅延する場合があります。
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
日中レンジ
現在 $6.39
52週レンジ
現在 $6.39
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
32
割高
センチメント
62
強気
リスク
70
高リスク
モメンタム
60
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
日中レンジ
現在 $6.39
52週レンジ
現在 $6.39
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | — | 702.5万 USD | 565.6万 USD |
| 売上原価 | — | 213.3万 USD | 170.7万 USD | — | — |
| 粗利益 | — | −213.3万 USD | −170.7万 USD | 702.5万 USD | 565.6万 USD |
| 研究開発 | 1.34億 USD | 1.12億 USD | 4821.6万 USD | 2840.2万 USD | 2585.2万 USD |
| 販売・一般管理 | 3610.7万 USD | 3013.1万 USD | 1248.3万 USD | 800.7万 USD | 615万 USD |
| 営業費用 | 1.7億 USD | 1.4億 USD | 6069.9万 USD | 3640.9万 USD | 3200.2万 USD |
| 受取利息 | 909.4万 USD | 1535.9万 USD | 228.2万 USD | 56.5万 USD | 1000 USD |
| 支払利息 | 48.9万 USD | 14.2万 USD | 18.7万 USD | 6.5万 USD | 3000 USD |
| 減価償却費と償却費 | 179.9万 USD | 213.3万 USD | 170.7万 USD | 105.1万 USD | 58.6万 USD |
| 営業利益 | −1.7億 USD | −1.43億 USD | −6240.6万 USD | −2938.4万 USD | −2634.6万 USD |
| 純利益 | −1.61億 USD | −1.27億 USD | −6036.6万 USD | −2889.3万 USD | −2635万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$25.00
上昇余地（291.24%）価格履歴は利用できません
最高：$25.00平均：$25.00最低：$25.00評価サンプルは4件と限定的です
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1189.63万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM696.8万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF370.26万0.00%954億 USD0.05%$235+0.80%
Fidelity Enhanced Small Cap ETFFESM305.14万0.05%64.1億 USD0.28%$45.46+0.46%
Vanguard Russell 2000 ETFVTWO204.41万0.01%180億 USD0.06%$112.66+0.50%
iShares Biotechnology ETFIBB180.5万0.02%108.2億 USD0.44%$206.49+3.00%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP160.7万0.06%26.06億 USD0.20%$66.35+1.13%
Schwab U.S. Small-Cap ETFSCHA118.62万0.01%218.24億 USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBState Street SPDR S&P Kensho New Economies Composite ETFKOMPSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
